Dr. Jorge E. Cortes CML Chronic Myeloid Leukemia
Jorge E. Cortes, MD is the director of the Georgia Cancer Center. Cortes joined the Cancer Center on September 1, 2019 after spending 23 years at The University of Texas MD Anderson Cancer Center.
Extract of Cancer Center Leadership, Augusta University
VIDEOS
Key topics at ESH CML 2022
October 21, 2022, VJHemOnc – Video Journal of Hematological Oncology
Working towards a cure in CML
June 16, 2022, VJHemOnc – Video Journal of Hematological Oncology
Bosutinib in newly diagnosed CML: GI, liver, effusion, and renal safety characterization (Dr. Jorge Cortes)
June 14, 2022, VJHemOnc – Video Journal of Hematological Oncology
CML : New Efficacy and Safety Results for Asciminib (Dr. Jorge Cortes)
June 7, 2022, The ASCO Post
CML: Asciminib Use in Later-Line Chronic Myeloid Leukemia
February 9, 2022, OncLive
Chronic Myeloid Leukemia: Assessing Treatment Response
January 19, 2022, OncLive
Dr. Cortes on Emerging Therapies in CML
September 8, 2021, OncLive
Dr. Cortes on the Future of Ponatinib in CML Treatment
January 18, 2021, OncLive
Chronic Myeloid Leukemia: Futuristic Views
August 7, 2020, Manage Health Foundation MHF
Dr. Cortes on the 192-Week Follow-Up Results of the ENESTop Trial in CML
August 30, 2019, OncLive
Treatment-Free Remission & Toxicities of Discontinuing CML Therapy
July 19, 2019, Targeted Oncology
Dr. Cortes Discusses TKI Cessation in CML
September 13, 2018, OncLiveTV
PACE Trial: Phase II trial of ponatinib in patients with chronic myeloid leukaemia (CML)
January16, 2018, ecancer
Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment
December 18, 2017, OBRoncology
Meet leukemia oncologist Jorge Cortes
October 25, 2017, MD Anderson Cancer Center
Faster, Better, Safer—Getting CML Treatment Right
December 23, 2016, PeerView Oncology
Study Brings Positive Results For the Most Resistant Types of CML
December 11, 2012, Patient Power
Dr. Jorge Cortes Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial
June 14, 2012, OncLive
New Help for More CML Patients: Dr. Jorge Cortes
December 20, 2010, Patient Power
CML: The Current Landscape - an interview with Dr. Jorge Cortes
October 2010, The National CML Society (US)
CML Treatment: Old Drug, New Name
December 18, 2009, ElsGlobalMedicalNews
ARTICLES
Adaptation Is Key to Advancing Care for Adult Patients With Leukemia
December 21, 2021, OncLive
How the Study of Leukemias Inspired a Decades-Long Career
November 14, 2021, Cancer Network
13 physicians named America’s Top Doctors for 2019
March 29, 2019, Augusta University
Cancer center’s new chief starts transition
March 11, 2019, The Augusta Chronicle
Dr. Jorge Cortes - Renowned clinical investigator selected as director for the Georgia Cancer Center
February 27, 2019, Augusta University
FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML
December 19, 2017, OncLive
Dr. Jorge Cortes Joins Dr. Andre Goy and Dr. Sagar Lonial as Co-Chair for the Landmark Physicians’ Education Resource® International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
September 06, 2017, Business Wire
How I treat newly diagnosed chronic phase CML
August 16, 2012, Journal Blood
Adaptation Is Key to Advancing Care for Adult Patients With Leukemia
December 21, 2021, OncLive
How the Study of Leukemias Inspired a Decades-Long Career
November 14, 2021, Cancer Network
13 physicians named America’s Top Doctors for 2019
March 29, 2019, Augusta University
Cancer center’s new chief starts transition
March 11, 2019, The Augusta Chronicle
Dr. Jorge Cortes - Renowned clinical investigator selected as director for the Georgia Cancer Center
February 27, 2019, Augusta University
FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML
December 19, 2017, OncLive
Dr. Jorge Cortes Joins Dr. Andre Goy and Dr. Sagar Lonial as Co-Chair for the Landmark Physicians’ Education Resource® International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
September 06, 2017, Business Wire
How I treat newly diagnosed chronic phase CML
August 16, 2012, Journal Blood
Modes of access to the website
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website. .
(No registration required - Anonymous access)
1 - Public access (strongly recommended)
On several occasions, the CML patient called CMLer will need a password to access several modules of the website. .
(No registration required - Anonymous access)
2 - Reserved access to CMLeukemia private group
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).
On other occasions, the more experienced patients will need more up-to-date or in-depth information. Among other upcoming modules, they will need access to the archives and also to abstracts of congresses on CML.
(Member password required and registration required).
